In accordance with our finding that consensus upregulated B cell genes could be utilized to predict the overall survival of CSCC, HLA-DPA1, IGHA2, CD52, HLA-DRB1, and GZMA are testified as prognostic markers for gynecological tumors, providing a theoretical basis for their use as targets in clinical immunotherapy [26–28]. Here, CD52 is linked to female reproductive system neoplasm.